Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
NCT05005429Phase 2Completed
- Sponsor
- Fundación GECP
- Start
- Sep 2021
- Primary completion
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bintrafusp alfa in malignant pleural mesothelioma (MPM), sponsored by Fundación GECP. Primary endpoint: Progression-Free Survival up to 2 years. Started Sep 2021; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT05005429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005429.